Persistently Low Immunereactivity As Determined by PHA-Induced ATP Release is Associated with Inferior Outcome in Allogeneic Hematopoietic Stem Cell Transplantation
A. Atasoy,M. Dunn,H. Wang,K. J. Spichty,D. Lenzner,A. Raptis,M. Agha,J. -Z Hou,A. Zeevi,M. Y. Mapara
DOI: https://doi.org/10.1016/j.bbmt.2009.12.207
2010-01-01
Biology of Blood and Marrow Transplantation
Abstract:Graft versus Host Disease (GVHD) and infectious complications are the main cause of morbidity and mortality after allogeneic blood or marrow transplantation (allo-BMT). Currently, there is no objective laboratory assay to assess the level of immunereactivity to potentially predict the risk of complications in allo-BMT patients. The Cylex ImmuKnow™ assay is approved by the US Food and Drug Administration for detection of cell mediated immunity in immunosuppressed individuals. This assay measures immune response to stimulation by detecting ATP synthesis in CD4 T cells following phytohemagglutinin (PHA) stimulation. We prospectively studied PHA-induced ATP release in 20 allo-BMT patients weekly from day +15 until day +100 post-transplantation. We tested 224 blood samples with an average of 11.2 per patient (SD 1.8). Patients received grafts from matched unrelated (MUD, n=11 [55%]), matched related (MRD, n=8 [40]) and syngeneic donors (n=1). Myeloablative and nonmyeloablative conditioning regimens were used in 13 (65%) and 7 (35%) patients, respectively. 12 patients (60%) developed GVHD requiring treatment, 2 (10%) developed GVHD which did not require treatment, and 6 (30%) did not develop any GVHD. Cyclosporine levels (n=19) did not correlate with ATP response, nor did the graft composition (CD34+ cells/kg or the CD3+ cells/kg). Further, we determined that the maximum ATP level was not a significant predictor of GVHD incidence, nor was the maximum fold increase over baseline. However, we observed worse outcomes in patients who had sustained low ATP levels as defined by 3 consecutive measurements of ATP <75 ng/mL. We found a significant correlation between persistently suppressed ATP levels and death (p=0.013). In all patients who died (n=7), ATP levels were persistently low and did not recover. In contrast, all 9 patients who exhibited ATP levels >75ng/ml are alive. Patients who maintained an average of >100 ng/ml ATP (mean 235 ng/ML, range 114-402 ng/mL) at monthly intervals did not have GVHD (n=6) or require therapy for GVHD (n=2). Conversely, patients with ATP levels <100 ng/mL at monthly intervals were treated for GVHD (mean 84.4 ng/mL, range 24-318ng/mL). Our data suggest that a persistent immunocompromised state in BMT recipients is associated with poor outcome. A larger study is warranted to analyze the utility of the Cylex ImmuKnow™ assay in BMT patients, which may enable us to predict outcomes and tailor immunosuppressive therapy.